AMPE - Ampio Pharmaceuticals posts early positive results in inhaled Ampion COVID-19 trial

Ampio Pharmaceuticals ([[AMPE]] +4.7%) revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19.The company also outlined its progress toward initiating a Phase I clinical trial using inhaled Ampion for treating those suffering lingering respiratory effects after COVID-19 infection, the so-called COVID-19 "long haulers," as well as its continued research focusing on the use of Ampion in kidney and pediatric diseases.Ampion showed an improvement in all-cause mortality in COVID-19 patients compared to standard of care ((SOC)). A lower all-cause mortality rate of 8% is observed for the treatment group, compared to 21% in standard of care alone.Patients who received Ampion required less hospitalization time, and the average hospital length of stay was 7 days for the Ampion group compared to 11 days for standard of care patients.The Ampion group required less oxygen than standard of care

For further details see:

Ampio Pharmaceuticals posts early positive results in inhaled Ampion COVID-19 trial